Alpha 2.0
Login Register
» Articles » PMID: 32370478

[Chinese Expert Consensus on Lipid Management of Very High-risk Atherosclerotic Cardiovascular Disease Patients]

Overview
Journal Zhonghua Xin Xue Guan Bing Za Zhi
Specialty Cardiology & Vascular Diseases
Date 2020 May 7
PMID 32370478
Citations 10
Affiliations
Soon will be listed here.
Citing Articles

Assessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial.

Gao B, Nan N, Zhang M, Tian J, Ren Y, Xue Y Cardiovasc Diagn Ther. 2025; 14(6):1236-1246.

PMID: 39790185 PMC: 11707485. DOI: 10.21037/cdt-24-336.

Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis.

Wu X, Ye X, Liu X, Lin Y, Lin X, Li Y Ann Med. 2024; 56(1):2389470.

PMID: 39126262 PMC: 11318487. DOI: 10.1080/07853890.2024.2389470.

LDL-C rebound after long-term evolocumab treatment and intravascular imaging evidence in a familial hypercholesterolemia patient with early-onset myocardial infarction.

Li Z, Zhang S, Yin Z, Zhang W, Sui Y, Li J Chronic Dis Transl Med. 2024; 10(1):69-74.

PMID: 38450306 PMC: 10914014. DOI: 10.1002/cdt3.97.

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.

Wan Y, Liu J, Zhan X, Zhang Y, You R Cost Eff Resour Alloc. 2023; 21(1):93.

PMID: 38041072 PMC: 10690971. DOI: 10.1186/s12962-023-00501-4.

2023 China Guidelines for Lipid Management.

Li J, Zhao S, Zhao D, Lu G, Peng D, Liu J J Geriatr Cardiol. 2023; 20(9):621-663.

PMID: 37840633 PMC: 10568545. DOI: 10.26599/1671-5411.2023.09.008.